Fintel reports that on August 8, 2023, Chardan Capital maintained coverage of CRISPR Therapeutics (NASDAQ:CRSP) with a Buy recommendation.
Analyst Price Forecast Suggests 77.89% Upside
As of August 1, 2023, the average one-year price target for CRISPR Therapeutics is 85.99. The forecasts range from a low of 42.42 to a high of $231.00. The average price target represents an increase of 77.89% from its latest reported closing price of 48.34.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for CRISPR Therapeutics is 153MM, a decrease of 9.84%. The projected annual non-GAAP EPS is -8.38.
What is the Fund Sentiment?
There are 583 funds or institutions reporting positions in CRISPR Therapeutics. This is a decrease of 12 owner(s) or 2.02% in the last quarter. Average portfolio weight of all funds dedicated to CRSP is 0.29%, an increase of 14.79%. Total shares owned by institutions increased in the last three months by 0.58% to 70,095K shares. 
The put/call ratio of CRSP is 0.45, indicating a bullish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 7,338K shares representing 8.80% ownership of the company. In it's prior filing, the firm reported owning 7,990K shares, representing a decrease of 8.88%. The firm increased its portfolio allocation in CRSP by 9.81% over the last quarter.
Capital International Investors holds 6,024K shares representing 7.23% ownership of the company. In it's prior filing, the firm reported owning 5,355K shares, representing an increase of 11.11%. The firm increased its portfolio allocation in CRSP by 19.96% over the last quarter.
ARKK - ARK Innovation ETF holds 5,394K shares representing 6.47% ownership of the company. In it's prior filing, the firm reported owning 5,451K shares, representing a decrease of 1.05%. The firm increased its portfolio allocation in CRSP by 8.35% over the last quarter.
Nikko Asset Management Americas holds 3,972K shares representing 4.77% ownership of the company. In it's prior filing, the firm reported owning 4,006K shares, representing a decrease of 0.86%. The firm decreased its portfolio allocation in CRSP by 12.21% over the last quarter.
T. Rowe Price Investment Management holds 3,664K shares representing 4.40% ownership of the company. In it's prior filing, the firm reported owning 2,994K shares, representing an increase of 18.31%. The firm increased its portfolio allocation in CRSP by 27.26% over the last quarter.
CRISPR Therapeutics Background Information
(This description is provided by the company.)
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Additional reading:
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent B
- FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA - - FDA grants Priority R
- Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress - Both trials met the primary and key secondary endp
- Amended and Restated Articles of Association (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 9, 2023).
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
